Literature DB >> 8386192

Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model.

D A Dodd1, J B Atkinson, R D Olson, S Buck, B J Cusack, S Fleischer, R J Boucek.   

Abstract

Doxorubicin is a highly effective cancer chemotherapeutic agent that produces a dose-dependent cardiomyopathy that limits its clinical usefulness. Clinical and animal studies of morphological changes during the early stages of doxorubicin-induced cardiomyopathy have suggested that the sarcoplasmic reticulum, the intracellular membrane system responsible for myoplasmic calcium regulation in adult mammalian heart, may be the early target of doxorubicin. To detect changes in the calcium pump protein or the calcium release channel (ryanodine receptor) of the sarcoplasmic reticulum during chronic doxorubicin treatment, rabbits were treated with intravenous doxorubicin (1 mg/kg) twice weekly for 12 to 18 doses. Pair-fed controls received intravenous normal saline. The severity of cardiomyopathy was scored by light and electron microscopy of left ventricular papillary muscles. Developed tension was measured in isolated atrial strips. In subcellular fractions from heart, [3H]ryanodine binding was decreased in doxorubicin-treated rabbits (0.33 +/- 0.03 pmol/mg) compared with control rabbits (0.66 +/- 0.02 pmol/mg; P < 0.0001). The magnitude of the decrease in [3H]ryanodine binding correlated with both the severity of the cardiomyopathy graded by pathology score (light and electron microscopy) and the decrease in developed tension in isolated atrial strips. Bmax for [3H]ryanodine binding and the amount of immunoreactive ryanodine receptor by Western blot analysis using sequence-specific antibody were both decreased, consistent with a decrease in the amount of calcium release channel of sarcoplasmic reticulum in doxorubicin-treated rabbits. In contrast, there was no decrease in the amount or the activity of the calcium pump protein of the sarcoplasmic reticulum in doxorubicin-treated rabbits. Doxorubicin treatment did not decrease [3H]ryanodine binding or the amount of immunoreactive calcium release channel of sarcoplasmic reticulum in skeletal muscle. Since the sarcoplasmic reticulum regulates muscle contraction by the cyclic uptake and release of a large internal calcium pool, altered function of the calcium release channel could lead to the abnormalities of contraction and relaxation observed in the doxorubicin cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386192      PMCID: PMC288149          DOI: 10.1172/JCI116379

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Drug-induced Ca2+ release from isolated sarcoplasmic reticulum. II. Releases involving a Ca2+-induced Ca2+ release channel.

Authors:  P Palade
Journal:  J Biol Chem       Date:  1987-05-05       Impact factor: 5.157

2.  Direct photoaffinity labeling of junctional sarcoplasmic reticulum with [14C]doxorubicin.

Authors:  F Zorzato; A Margreth; P Volpe
Journal:  J Biol Chem       Date:  1986-10-05       Impact factor: 5.157

Review 3.  Subcellular effects of adriamycin in the heart: a concise review.

Authors:  P K Singal; C M Deally; L E Weinberg
Journal:  J Mol Cell Cardiol       Date:  1987-08       Impact factor: 5.000

4.  Mechanism of anthraquinone-induced calcium release from skeletal muscle sarcoplasmic reticulum.

Authors:  J J Abramson; E Buck; G Salama; J E Casida; I N Pessah
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

5.  Isolation and characterization of the inositol trisphosphate receptor from smooth muscle.

Authors:  C C Chadwick; A Saito; S Fleischer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

6.  Sulfhydryl oxidation induces rapid calcium release from sarcoplasmic reticulum vesicles.

Authors:  J L Trimm; G Salama; J J Abramson
Journal:  J Biol Chem       Date:  1986-12-05       Impact factor: 5.157

7.  Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.

Authors:  R G Schwartz; W B McKenzie; J Alexander; P Sager; A D'Souza; A Manatunga; P E Schwartz; H J Berger; J Setaro; L Surkin
Journal:  Am J Med       Date:  1987-06       Impact factor: 4.965

8.  Ca2+ release from sarcoplasmic reticulum of skinned fast- and slow-twitch muscle fibers.

Authors:  G Salviati; P Volpe
Journal:  Am J Physiol       Date:  1988-03

9.  The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions.

Authors:  R J Boucek; R D Olson; D E Brenner; E M Ogunbunmi; M Inui; S Fleischer
Journal:  J Biol Chem       Date:  1987-11-25       Impact factor: 5.157

10.  The role of lipid peroxidation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart.

Authors:  R H Julicher; L Sterrenberg; A Bast; R O Riksen; J M Koomen; J Noordhoek
Journal:  J Pharm Pharmacol       Date:  1986-04       Impact factor: 3.765

View more
  21 in total

1.  Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2+) handling and contractile function in rat heart.

Authors:  R Zucchi; G Yu; S Ghelardoni; F Ronca; S Ronca-Testoni
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 2.  Rodent models of heart failure: an updated review.

Authors:  A C Gomes; I Falcão-Pires; A L Pires; C Brás-Silva; A F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

3.  Effects of mitoxantrone on action potential and membrane currents in isolated cardiac myocytes.

Authors:  G X Wang; X B Zhou; T Eschenhagen; M Korth
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 4.  Imaging of early modification in cardiomyopathy: the doxorubicin-induced model.

Authors:  Mohamed Aissiou; Delphine Périé; Farida Cheriet; Nagib S Dahdah; Caroline Laverdière; Daniel Curnier
Journal:  Int J Cardiovasc Imaging       Date:  2013-06-07       Impact factor: 2.357

Review 5.  Cardiotoxicity of anticancer treatments: what the cardiologist needs to know.

Authors:  Michael S Ewer; Steven M Ewer
Journal:  Nat Rev Cardiol       Date:  2010-10       Impact factor: 32.419

6.  Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat.

Authors:  B E Burke; H Gambliel; R D Olson; F K Bauer; B J Cusack
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

7.  Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.

Authors:  Daniel H Breysse; Ryan M Boone; Cameron M Long; Miranda E Merrill; Christopher M Schaupp; Collin C White; Terrance J Kavanagh; Edward E Schmidt; Gary F Merrill
Journal:  Drug Metab Dispos       Date:  2020-01-18       Impact factor: 3.922

8.  A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish.

Authors:  Xiao Ma; Yonghe Ding; Yong Wang; Xiaolei Xu
Journal:  J Vis Exp       Date:  2018-06-07       Impact factor: 1.355

9.  Differential regulation of two types of intracellular calcium release channels during end-stage heart failure.

Authors:  L O Go; M C Moschella; J Watras; K K Handa; B S Fyfe; A R Marks
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

10.  Mechanism of doxorubicin cardiotoxicity evaluated by integrating multiple molecular effects into a biophysical model.

Authors:  M Fernandez-Chas; M J Curtis; S A Niederer
Journal:  Br J Pharmacol       Date:  2018-01-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.